NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis

eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage

Roche’s PiaSky approved in the EU for treatment of people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration

Merck announces first patient dosed in Phase III study of Oral Cladribine in gMG

MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)

Govt. to improve availability of infrastructure and trained manpower for organ transplantation

Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country

Biocon Pharma receives USFDA approval for daptomycin

The approval further adds to Biocon’s portfolio of complex drug products

Thyrocare to acquire diagnostic and pathological services business of Vimta Labs

Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025

Indian doctor participates in Jordan’s first robotic radical hysterectomies

Bayer awards incubator opportunity to Genvor

Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies

Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan

Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025

Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration